CCS and Alzheimer disease: Quantitative evaluations of these 1D‐WB signals confirmed significantly lower amounts of CCS and GPX1 in the frontal lobes of AD cases (CCS: FCAD/Co = 0.37; p = 0.008 and GPX1: FCAD/Co = 0.73; p = 0.005; Figure 6B,C) and AD platelets (CCS: FCAD/Co = 0.15; p = 0.002 and GPX1: FCAD/Co = 0.35; p = 0.001; Figure 6B,C).